New knowledge of epigenetics and biology promises new treatments that are much more precise and effective. A strong American pharmaceutical industry is essential. The current American pharmaceutical industry needs substantial reform to deliver on that promise. In the last post, I wrote about an industry that does not serve the American people well. The worst example is the home-grown opioid epidemic. Industry and politicians collaborated in this scourge. The industry needs much more reform and there are three stakeholder groups that are being harmed by the status quo that should press the issue and demand an industry that serves Americans better.
Healthcare providers cannot depend on reliable information from industry influenced journal articles on new drugs to guide treatment for their patients. They should push hard for editorial and reviewer access to the raw data from the clinical trials. Stakeholders should be involved in clinical trial design and monitoring. Drug pricing must be negotiated for all medication and it should begin now. Health care providers should push hard for these reforms
Self-insured employers and governmental entities at every level pay for most medical costs. When these costs are inflated, it costs taxpayers more and makes our industry much less competitive. Non-medical self-insured employers have a very high stake in drug industry reform and drug price negotiation and they should push hard to achieve it.
American people suffer the most from not having accurate information on drug benefits and harms. Medical costs are a leading cause of bankruptcy and that is unusual in other developed countries. The American people will benefit the most from negotiated drug prices and more accurate information about medications. They will benefit the most from information on the combinations of treatments that are most effective for diseases like diabetes. They should vote for politicians who are committed to drug industry reform that leads to a system that serves all of us better.
We know these changes will not happen without action and pressure. They will not happen if you do nothing. Join us in pressing for a healthcare system that serves us all better.
PBMs obscure pricing for purchasers. Most purchasers don’t know how to negotiate the costs of drugs even when given the opportunity. In addition, their consultants and advisors don’t either. Even more troubling is the fact that most providers do a poor job understanding the efficacy of the drugs that they prescribe. Our analysis of very large employer claims data proves this out where we were able to apportion NDC11 data to diagnosis. The opportunity to create optimized efficacy is here now. We know what the FDA endpoints (goals) are for specific drugs. So, while negotiating prices on drugs is a good first step; there are many other opportunities to make drug purchasing and drug prescribing.......better and more focused on optimized outcomes for patients.
Yes. Our the central element of this revolutionary change is to establish an independent, decentralized, individually owned and monetized, grassroots monitored, managed, and vetted data networks designed for the 21st Century to allow thorough reproducible verification and validation of ALL the devices, tests, procedures, and most importantly the pharmaceuticals to ensure that they indeed are safe and effective without the politics, the corruption, and the gaslighting of the masses. No more lies, deception, and plundering of public funding. We must deliver the best outcomes for the lowest cost and the safest, and most effective everything we prescribe to serve our patients with transparency, integrity, and honesty. This GRASS ROOT Uprising will save mankind from ruins of the “expert opinions” driven late stage sickness seeking profiteering 19th Century Legacy American Medical Industrial Complex Kabuki Dance Theatrics! ENOUGH!